Serum matrix metalloproteinase 9 and colorectal neoplasia: A community-based evaluation of a potential diagnostic test

British Journal of Cancer

Volumn 106, Issue 8, 2012, Pages 1431-1438

  Wilson, S ^a   Damery, S ^a   Stocken, D D ^a   Dowswell, G ^a   Holder, R ^a   Ward, S T ^b   Redman, V ^a   Wakelam, M J ^a,c   James, J ^a   Hobbs, F D R ^d   Ismail, T ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^c BABRAHAM INSTITUTE   (United Kingdom)

^d Department of Primary Care Health Sciences ^*  (United Kingdom)

Author keywords

colorectal cancer; diagnosis; matrix metalloproteinase; risk; screening; serum

Indexed keywords

BIOLOGICAL MARKER; GELATINASE B;

ADULT; AGED; ARTICLE; BEHAVIOR; CANCER RISK; COHORT ANALYSIS; COLONOSCOPY; COLORECTAL TUMOR; COMMUNITY ASSESSMENT; CONTROLLED STUDY; DEMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GASTROINTESTINAL SYMPTOM; HEALTH SURVEY; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; SYMPTOM; UNIVARIATE ANALYSIS;

AGED; COHORT STUDIES; COLORECTAL NEOPLASMS; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; SENSITIVITY AND SPECIFICITY;

EID: 84859626920     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.93     Document Type: Article

References (41)

1. Adelstein BA, Irwig L, Macaskill P, Katelaris PH, Jones DB, Bokey L (2008) A self administered reliable questionnaire to assess lower bowel symptoms. BMC Gastroenterol 8: 8
2. Arditi C, Peytremann-Bridevaux I, Burnand B, Eckardt VF, Bytzer P, Agreus L, Dubois RW, Vader JP, Froehlich F, Pittet V, Schussele Filliettaz S, Juillerat P, Gonvers JJ (2009) Appropriateness of colonoscopy in Europe (EPAGE II). Screening for colorectal cancer. Endoscopy 41: 200-208
3. Atkin WS (2006) Impending or pending? The national bowel cancer screening programme. BMJ 332: 742
4. Atkin WS, Saunders BP (2002) Surveillance guidelines after removal of colorectal adenomatous polyps. Gut 51(Suppl 5): V6-V9 (Pubitemid 35222897)
5. Atkin WS, Edwards R, Kralj-Hans I, Wooldrage K, Hart AR, Northover JMA, Parkin DM, Wardle J, Duffy SW, Cuzick J (2010) Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 375: 1624-1633
6. Baker EA, Leaper DJ (2003) The plasminogen activator and matrix metalloproteinase systems in colorectal cancer: relationship to tumour pathology. Eur J Cancer 39: 981-988 (Pubitemid 36428631)
7. Cancer Research UK (2010a) Bowel (colorectal) cancer-UK incidence statistics. http://info.cancerresearchuk.org/cancerstats/types/bowel/incidence/ index.htm
8. Cancer Research UK (2010b) Bowel (colorectal) cancer - UK mortality statistics. http://info.cancerresearchuk.org/cancerstats/types/bowel/mortality/ index.htm
9. Cancer Research UK (2010c) Bowel cancer - survival statistics. http://info.cancerresearchuk.org/cancerstats/types/bowel/survival/index.htm
10. Chen CD, Yen MF, Wang WM, Wong JM, Chen TH (2003) A case-cohort study for the disease natural history of adenoma-carcinoma and de novo carcinoma and surveillance of colon and rectum after polypectomy: implication for efficacy of colonoscopy. Br J Cancer 88: 1866-1873
11. Collins HM, Morris TM, Watson SA (2001) Spectrum of matrix metalloproteinase expression in primary and metastatic colon cancer: relationship to the tissue inhibitors of metalloproteinases and membrane type-1-matrix metalloproteinase. Br J Cancer 84: 1664-1670 (Pubitemid 32612499)
12. Department of Health (2007) NHS Cancer Reform Strategy. Department of Health: London
13. Dragutinovic V, Izrael-Zivkovic L, Radovanovic N (2009) Relation of matrix metalloproteinase-9 to different stages of tumors in the serum of gastric cancer. Dig Dis Sci 54: 1203-1207
14. Dragutinovic VV, Radonjic NV, Petronijevic ND, Tatic SB, Dimitrijevic IB, Radovanovic NS, Krivokapic ZV (2011) Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) in preoperative serum as independent prognostic markers in patients with colorectal cancer. Mol Cell Biochem 355: 173-178
15. Garbett EA, Reed MW, Brown NJ (1999) Proteolysis in human breast and colorectal cancer. Br J Cancer 81: 287-293 (Pubitemid 29423707)
16. Gerlach RF, Demacq C, Jung K, Tanus-Santos JE (2007) Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma. Clin Biochem 40: 119-123 (Pubitemid 46014168)
17. Gerlach RF, Meschiari CA, Marcaccini AM, Palei AC, Sandrim VC, Cavalli RC, Tanus-Santos JE (2009) Positive correlations between serum and plasma matrix metalloproteinase (MMP)-2 or MMP-9 levels in disease conditions. Clin Chem Lab Med 47: 888-891
18. Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, James PD, Mangham CM (1996) Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 348: 1472-1477 (Pubitemid 26400242)
19. Heslin MJ, Yan J, Johnson MR, Weiss H, Diasio RB, Urist MM (2001) Role of matrix metalloproteinases in colorectal carcinogenesis. Ann Surg 233: 786-792 (Pubitemid 32494559)
20. Hewitson P, Irwig L, Towler B, Watson E (2007) Screening for colorectal cancer using the faecal occult blood test, Hemoccult (review). Cochrane Database Sys Rev 1: CD001216
21. Hurst NG, Stocken DD, Wilson S, Keh C, Wakelam MJ, Ismail T (2007) Elevated serum matrix metalloproteinase 9 (MMP-9) concentration predicts the presence of colorectal neoplasia in symptomatic patients. Br J Cancer 97: 971-977 (Pubitemid 47519304)
22. Juillerat P, Peytremann-Bridevaux I, Vader JP, Arditi C, Schussele Filliettaz S, Dubois RW, Gonvers JJ, Froehlich F, Burnand B, Pittet V (2009) Appropriateness of colonoscopy in Europe (EPAGE II). Presentation of methodology, general results, and analysis of complications. Endoscopy 41: 240-246
23. Jung K (2008) Is serum matrix metalloproteinase 9 a useful biomarker in detection of colorectal cancer? Considering pre-analytical interference that may influence diagnostic accuracy. Br J Cancer 99: 553-554; author reply 555
24. Jung K, Klotzek S, Stephan C, Mannello F, Lein M (2008) Impact of blood sampling on the circulating matrix metalloproteinases 1, 2, 3, 7, 8, and 9. Clin Chem 54: 772-773
25. Lieberman DA, Weiss DG, Bond JH, Ahnen DJ, Garewal H, Chejfec G (2000) Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. N Engl J Med 343: 162-168 (Pubitemid 30489212)
26. Macafee D, Gemmill L, Lund J (2006) Colorectal cancer: current care, future innovations and economic considerations. Expert Rev Pharmacoecon Outcomes Res 6: 195-206
27. Makowski GS, Ramsby ML (2003) Use of citrate to minimise neutrophil matrix metalloproteinase-9 in human plasma. Anal Biochem 322: 283-286. (Pubitemid 37330086)
28. Motovali-Bashi M, Sadeghi M, Hemmati S (2010) Serum MMP-9 level associated with initiation and progression steps of breast cancer in the Iranian population. Reprod Sci 17: 585-589
29. National Cancer Institute (2010) Surveillance, survival and end results. Stat Fact Sheets
30. National Institute for Health and Clinical Excellence (NICE) (2005) Referral guidelines for suspected cancer: Clinical guidelines CG2
31. Office for National Statistics (2004) Mid-2002 Population Estimates; quinary age groups and sex for local authorities in England and Wales; estimated resident population. http://www.statistics.gov.uk/statbase/Product.asp?vlnk= 10687&image.x=18&image.y=9
32. Office for National Statistics (2005) T 15: Mid-2005 Population Estimates; Quinary age groups and sex for Primary Care Organisations (PCOs) for England; estimated resident population (experimental). On boundaries as at 1 October 2006 http://www.statistics.gov.uk/StatBase/ssdataset.asp?vlnk= 9585&Pos=2&ColRank=1&Rank=96
33. Office for National Statistics (2010) Bowel cancer. Colorectal cancer incidence and mortality by sex, England, 1971-2007. http://www.statistics.gov. uk/CCI/nugget.asp?ID=2162&Pos=&ColRank=1&Rank=374
34. Parsons SL, Watson SA, Collins HM, Griffin NR, Clarke PA, Steele RJ (1998) Gelatinase (MMP-2 and -9) expression in gastrointestinal malignancy. Br J Cancer 78: 1495-1502 (Pubitemid 28517547)
35. Shen KH, Chi CW, Lo SS, Kao HL, Lui WY, Wu CW (2000) Serum matrix metalloproteinase-9 level associated with stromal reaction in patients with gastric cancer. Anticancer Res 20: 1307-1310
36. Thiis-Evensen E, Hoff GS, Sauar J, Majak BM, Vatn MH (1999) Flexible sigmoidoscopy or colonoscopy as a screening modality for colorectal adenomas in older age groups? Findings in a cohort of the normal population aged 63-72 years. Gut 45: 834-839
37. UK Colorectal Cancer Screening Pilot Group (2004) Results of the first round of a demonstration pilot of screening for colorectal cancer in the United Kingdom. BMJ 329: 133
38. Verne JE, Aubrey R, Love SB, Talbot IC, Northover JM (1998) Population based randomized study of uptake and yield of screening by flexible sigmoidoscopy compared with screening by faecal occult blood testing. BMJ 317: 182-185 (Pubitemid 28325545)
39. Weller D, Coleman D, Robertson R, Butler P, Melia J, Campbell C, Parker R, Patnick J, Moss S (2007) The UK colorectal cancer screening pilot: results of the second round of screening in England. Br J Cancer 97: 1601-1605 (Pubitemid 350249359)
40. Wilson S, Wakelam M, Hobbs FDR, Ryan A, Dunn J, Redman V, Patrick F, Colbourne L, Martin A, Ismail T (2006) Evaluation of the accuracy of serum MMP-9 as a test for colorectal cancer in a primary care population: study protocol. BMC Cancer 6: 258
41. Wu CY, Wu MS, Chiang EP, Chen YJ, Chen CJ, Chi NH, Shih YT, Chen GH, Lin JT (2007) Plasma matrix metalloproteinase-9 level is better than serum matrix metalloproteinase-9 level to predict gastric cancer evolution. Clin Cancer Res 13: 2054-2060